In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Adverse reactions attributed to entire drug class 'Epidermal growth factor receptor (EGFR) inhibitor / antagonist'
Please login to view adverse reactions.
Acneiform eruption / acneiform dermatitis / acneiform rash
- (2023): Yuan C+, J Cosmet Dermatol Mar, Online ahead of print [REVIEW]
- (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
- (2017): Tischer B+, Support Care Cancer 25(2), 651
- (2016): Clabbers JM+, Support Care Cancer 24(2), 513
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
- (2016): Sibaud V+, Clin Exp Dermatol 41(1), 34 (delayed)
- (2015): Lupu I+, J Med Life 8(Spec Issue), 57
- (2015): Melosky B+, Curr Oncol 22(2), 123
- (2015): Nakahara T+, Onco Targets Ther 8, 259
- (2012): Requena C+, Cutis 90(2), 77
- (2012): Thaler J+, BMC Cancer 12, 438
Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
Cutaneous toxicity / skin toxicity
- (2024): Lee JS+, Acta Derm Venereol 104, adv40555
- (2022): Lu CW+, J Eur Acad Dermatol Venereol Nov, Online ahead of print
- (2017): Monjazeb S+, Skin Therapy Lett 22(5), 5
- (2017): Stanculeanu DL+, Maedica (Buchar) 12(1), 48
- (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]
- (2014): Sinclair R, Asia Pac J Clin Oncol 10 Suppl 1, 11 [REVIEW]
- (2012): Requena C+, Cutis 90(2), 77
Eczema / eczematous reaction / eczematous eruption
- (2023): Zhang Y+, Clin Exp Dermatol Sep, Online ahead of print (3 cases / female) (pharmacogenomics)
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54711% [REVIEW]
Erythema dyschromicum perstans / ashy dermatosis
- (2024): Bang AS+, Support Care Cancer 32(6), 354 (16 cases)
- (2022): Liu HL+, J Oncol Pharm Pract Sep, Online ahead of print (22 cases)
Hand–foot syndrome (palmar–plantar erythrodysesthesia)
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2015): Lupu I+, J Med Life 8(Spec Issue), 57
- (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
- (2024): Bălăceanu-Gurău B+, Cureus 16(11), e72878
- (2019): Yalici-Armagan B+, Cutan Ocul Toxicol Apr, Epub ahead of print
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2016): Clabbers JM+, Support Care Cancer 24(2), 513
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54727% [REVIEW]
- (2012): Hello M+, Rev Med Interne (French) 33(5), 273
- (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]
- (2017): Lugovic-Mihic L+, Acta Clin Croat 56(2), 277 [REVIEW]
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2016): Clabbers JM+, Support Care Cancer 24(2), 51317%
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
- (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]
- (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
- (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
- (2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
- (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2014): Hirsh V+, Curr Oncol 21(6), 329
- (2014): Vaubel J+, J Eur Acad Dermatol Venereol 28(12), 1685
- (2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]
- (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2016): Clabbers JM+, Support Care Cancer 24(2), 51322%
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 54753% [REVIEW]
- (2012): Requena C+, Cutis 90(2), 77
- (2012): Thaler J+, BMC Cancer 12, 438
- (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2015): Herink C+, Hautarzt (German) 66(8), 617 (passim)
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
- (2011): Wu PA+, Curr Opin Oncol 23(4), 343 [REVIEW]
- (2012): Garden BC+, J Am Acad Dermatol 67(3), 400 [REVIEW]
- (2011): Wu PA+, Curr Opin Oncol 23 (4), 343
- (2014): Prescrire Int 23(151), 180
- (2012): Requena C+, Cutis 90(2), 77
- (2022): Liu HL+, J Oncol Pharm Pract Sep, Online ahead of print (22 cases)
- (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
- (2018): Sanmartin O, Curr Probl Dermatol 53, 93
- (2017): Owczarek W+, Postepy Dermatol Alergol 34(5), 418 [REVIEW]
- (2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5475% [REVIEW]
- (2015): Melosky B+, Curr Oncol 22(2), 123
- (2012): Hello M+, Rev Med Interne (French) 33(5), 273
- (2012): Thaler J+, BMC Cancer 12, 438
- (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
- (2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5477% [REVIEW]
- (2015): Ruiz JN+, Support Care Cancer 23(8), 2391 [REVIEW]
- (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
- (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2015): Melosky B+, Curr Oncol 22(2), 123
- (2024): Wang Y+, Front Oncol Jun (e-Collection) [REVIEW]
- (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
- (2016): Berger MD+, Expert Opin Drug Saf 15(6), 799 [REVIEW]
- (2016): Jiang DM+, Clin Colorectal Cancer 15(3), e117 [REVIEW]
- (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
- (2023): Cárdenas-Fernández D+, Ther Adv Med Oncol Aug (e-Collection) [REVIEW]
- (2021): Shi X+, Front Oncol May (e-Collection) [REVIEW]
- (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
- (2018): Aw DC+, Asia Pac J Clin Oncol 14(1), 23 [REVIEW]
- (2017): Chan DLH+, Cochrane Database Syst Rev 6, CD007047 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2014): Hirsh V+, Curr Oncol 21(6), 329
Gastrointestinal adverse reaction
- (2023): Zhang P+, Therap Adv Gastroenterol Apr (e-Collection) [REVIEW]
- (2022): Yu M+, Front Oncol Jun (e-Collection) 69% (abnormal menstruation)
Myelosuppression / bone marrow suppression / myelotoxicity
- (2021): Zhang L+, BMJ Open 11(3), e046352 [REVIEW]
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2015): Chanprapaph K+, Indian J Dermatol Venereol Leprol 81(5), 5472% [REVIEW]
- (2012): Thaler J+, BMC Cancer 12, 438
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
- (2017): Izzedine H+, Nephrol Dial Transplant 32(7), 1089
- (2023): Kashizaki F+, Clin Lung Cancer Oct, Online ahead of print14% [REVIEW]
- (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) (Reported as an adverse reaction event for patients with nasopharyngeal carcinoma following radiotherapy)
- (2020): Guo R+, Thorac Cancer 11(7), 2031-2035 (3 cases) (with microwave ablation)
- (2016): Vogel WH+, J Adv Pract Oncol 7(7), 723 [REVIEW]
- (2014): Johkoh T+, Clin Lung Cancer 15(6), 448
Adverse effects / adverse reactions
- (2024): An Z+, Laryngoscope Investig Otolaryngol 9(3), e1279 (grade 3–4) [REVIEW]
- (2023): Liao D+, Int Immunopharmacol Feb, Online ahead of print (with immune checkpoint inhibitor)
- (2020): Huang J+, Sci Rep 10(1), 4803 [REVIEW]
- (2020): Zhou JY+, Expert Opin Drug Saf Apr, Epub ahead of print [REVIEW]
- (2019): Zhao Y+, BMJ 367, 15460 [REVIEW]
- (2017): Below J+, Hautarzt (German) 68(1), 12 [REVIEW] (cutaneous)
- (2015): Sharma A+, Perspect Clin Res 6(2), 1091%
- (2024): Lai X+, Medicine (Baltimore) 103(23), e38277 [REVIEW] (association)
